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ABSTRACT
Objectives Amblyopia, strabismus and ocular motility 
disorders are common conditions with significant impact 
on visual function, appearance and quality of life. We 
aimed to establish a core set of outcomes for each of the 
three conditions for use in clinical trials and routine clinical 
practice.
Design A comprehensive databank of outcomes was 
developed from a systematic review of the literature and 
a series of focus groups with healthcare professionals, 
researchers, patients and carers. The databank of 
outcomes was scored in a two- round Delphi Survey 
completed by two stakeholder groups: healthcare 
professionals/researchers and patients/carers. Results 
of the online Delphi were discussed at a face- to- face 
consensus meeting where the core outcome sets were 
finalised.
Setting UK- wide consultation.
Participants Researchers, clinicians, patients and carers.
Outcome measures Core outcome sets.
Results For amblyopia, strabismus and ocular motility, 
40/42/33 participants contributed to both rounds of the 
Delphi; six/nine/seven members attended consensus 
meetings, respectively. Consensus was reached on ten 
core outcomes for both amblyopia and ocular motility and 
nine for strabismus. All three conditions shared the core 
outcomes: adverse events, cost, vision- related quality 
of life and ocular alignment. The strabismus and ocular 
motility disorder core sets included, in addition, measuring 
the deviation, binocular vision, ocular movement, patient 
satisfaction and symptoms. The amblyopia set, distinct 
from the sets for the other two conditions, included best 
corrected distance and near visual acuity, spherical and 
cylindrical refraction, compliance and treatment- related 
and functionality/long- term impacts.
Conclusions The study used robust consensus methods 
to develop a core outcome set for three ophthalmic 
conditions. Implementation of these core outcome sets in 
clinical trials and routine clinical practice will ensure that 
the outcomes being measured and reported are relevant to 
all stakeholders. This will enhance the relevance of study 
findings and enable comparison of results from different 
studies.
INTRODUCTION
Amblyopia (lazy eye) and strabismus (squint) 
occur in up to 5% of the general popula-
tion.1 2 It is unknown how prevalent ocular 
motility disorders (abnormal eye move-
ments) are in the general population. These 
conditions often present in children and can 
lead to long- term problems for children and 
young adults such as blurred vision, double 
vision, low esteem and even blindness if not 
treated.3 There are several approaches to the 
management of these conditions including 
occlusion, penalisation, spectacles, prisms, 
drugs, surgery, botulinum toxin, exercises, 
watchful waiting or a combination of two or 
more of the above.4–20
Interventional systematic reviews in this 
field of research have identified that there 
is considerable variation in the outcomes 
being measured and reported in primary 
research studies, which impacts on the ability 
to compare and synthesise outcome results 
across studies. Moreover, it was noted that 
there is a paucity of outcome data available 
on important patient outcomes such as 
Strengths and limitations of this study
 ► This study followed robust methodology as guided 
by the Core Outcome Measures in Effectiveness 
Trials Initiative.
 ► We targeted amblyopia, strabismus and ocular 
motility disorders, which are common ophthalmic 
conditions.
 ► The study included key stakeholders including re-
searchers, clinicians, patients and carers.
 ► Attrition rates in the Delphi process were moderate 
but similar to other Core Outcome Set Studies.
 ► Larger response numbers, including internation-
al participants, would be preferable for wider 
generalisability.
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quality of life, long- term outcome and the cost of treat-
ment.4–20 To mitigate these issues and to increase the 
relevance of research, a core outcome set (COS) can be 
developed, which represents an agreed standardised set 
of outcomes that should be measured and reported in 
all studies for a specific area of health or healthcare. A 
search of the Core Outcome Measures in Effectiveness 
Trials (COMET) database revealed that there are several 
studies that have investigated important outcomes for the 
eyes and vision disease; examples include cataract,21 22 
glaucoma23 and age- related macular degeneration,24 but 
none have specifically looked at amblyopia, strabismus or 
ocular motility disorders.25
The aim of this study was to develop COSs for use in 
clinical trials and routine practice for all intervention 
types for the treatment of amblyopia, strabismus and 
ocular motility disorders in children and adults that 
includes input from all stakeholders. While we aim to 
develop three separate COSs for each of the ophthalmic 
conditions, we anticipate that there could be consid-
erable overlap in the importance of certain outcomes 
across these conditions. This is due to the fact that the 
three conditions often overlap and coexist in patients, 
are frequently targeted within the same research studies, 
and are usually managed by the same group of healthcare 
professionals.
METHODS
The development of the COS Study involved three stages 
(figure 1): (1) the generation of a long list of outcomes, 
(2) a two- round online Delphi Survey and (3) face- to- face 
consensus meetings to discuss the results of the Delphi 
Survey and agree on the COS. The process considered 
the minimum standards for the design of a COS Study 
(Core Outcome Set—Standards for Development (COS- 
STAD)), which included careful consideration of the 
scope, stakeholders and consensus process.26
Outcome list generation
A databank of outcomes was generated from two 
sources: first, a systematic review of outcomes reported 
by researchers and clinicians in studies for the treatment 
of the conditions under evaluation and, second, using 
three separate focus groups (one for each condition) 
containing a mix of healthcare professionals, researchers, 
patients and carers. The detailed search strategy, methods 
and results for the systematic review have been published 
elsewhere.27 Outcomes from the systematic review and 
suggested outcomes from the recorded focus group meet-
ings were extracted verbatim and grouped into suitable 
domains to facilitate easy classification. The final list was 
checked by experts in all three clinical conditions (SA- J 
and FJR), who also had the opportunity to use their clin-
ical expertise to add additional outcomes to the list. In 
preparation for the Delphi Survey, clinical assessment 
outcomes used only by healthcare professionals were 
either separated out (not to be scored by patients) or 
combined into a simplified outcome for patients to score. 
Each outcome was written using plain language and 
feedback sought from four researchers from the health 
service research department, University of Liverpool, and 
a clinician from a local hospital on the acceptability and 
their understanding of the wording used. The databank 
of outcomes can be found in online supplemental table 1.
Online Delphi Survey
The databank of outcomes was used to populate an online 
Delphi Survey, which was administered using Delphi-
Manager.28 Participants were invited from two key stake-
holder groups. The first group consisted of healthcare 
professionals involved in the care for people with one of 
the three conditions or researchers working within this 
field. Invitations to participate were sent by email flyers to 
national professional organisations including the British 
and Irish Orthoptic Society, paediatric ophthalmology 
networks, and local groups linked with the University of 
Liverpool. The second group included patients or carers 
of patients affected by at least one of the three conditions 
of interest. Patients and carers were invited to participate 
into the survey using flyers distributed on the University 
of Liverpool noticeboards, newsletters (via the profes-
sional society), social media (Twitter) and ophthalmology 
departments in local hospitals including Aintree Univer-
sity Hospital, the Royal Liverpool University Hospital and 
Southport and Ormskirk hospitals. Through routine clin-
ical practice, the study authors (SA- J and FJR) and health-
care professionals were also encouraged to distribute 
the patient survey links to their relevant patients if they 
showed an interest in the study.
Four surveys were set up, one for the healthcare profes-
sionals and researchers that contained the outcomes to 
be scored for all three conditions and three separate 
surveys containing only the outcomes relevant to patients 
and carers associated with each individual condition. The 
Delphi process was completed using two rounds (here-
after referred to R1 and R2). In each round, participants 
were presented with the list of outcomes and asked to 
score each outcome on how important it was to include 
in the COS, using a 9- point Likert Scale, with 1–3 labelled 
‘not important’, 4–6 labelled ‘important but not crit-
ical’ and 7–9 labelled as ‘critically important’.29 Partici-
pants had the option to indicate ‘unable to score’ on any 
outcome they felt unable to score, and at the end of R1, 
participants were invited to submit additional outcomes 
they thought were missing from the list. These outcomes 
were reviewed by the study authors (SA- J and FJR), and 
any outcomes that represented a new relevant outcome 
were added to the list to be scored in R2. Irrespective of 
participant scoring, no outcomes were removed from 
the list between R1 and R2. During R2, participants were 
shown the distribution of scores for both stakeholder 
groups for each outcome along with their own score from 
R1 and asked to score the outcome again, using the same 
scale, taking this extra information into account.
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Consensus meeting
Separate face- to- face consensus meetings were held at 
the University of Liverpool, in the UK, for each of the 
three conditions. Participants who either had an active 
role in the focus groups or completed both rounds of the 
Delphi Survey were invited to attend, although others 
Figure 1 Study flowchart. (A amblyopia, S strabismus, OM ocular motility, HCP health care professional)
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with an interest in the project were invited to ensure each 
meeting had a balanced mix of participants from both 
stakeholder groups. In advance of the meeting, partici-
pants received a copy of their scores from the online 
survey (if appropriate) and a consensus matrix (online 
supplemental table 1) detailing the results of R1 and R2 
by stakeholder group and which outcomes had reached 
a priori definition of consensus in, consensus out or no 
consensus (table 1). The consensus definition is similar to 
that used in other COS development studies.
The meeting for amblyopia was chaired by a non- 
clinical researcher with expertise in COS development 
methodology (JJK), while the meeting for strabismus and 
ocular motility was chaired by an investigator with a clin-
ical background (SA- J).
In order to facilitate the discussion, all outcomes that 
had reached consensus ‘in’ after R2 for both stakeholder 
groups were presented first, followed by outcomes that 
reached consensus ‘in’ for only one stakeholder group. 
All outcomes that scored critical for inclusion for 
50%–69% of the participants for either both or one of the 
stakeholder groups in R2 were presented next followed 
by all other outcomes that were scored by both stake-
holder groups. Outcomes that were only scored by health-
care professionals and researchers were discussed last. 
Results for each outcome from the Delphi were shown 
to the participants with more time allocated to discussing 
outcomes where there was more uncertainty on whether 
the outcome should be included in the COS or not. Views 
for and against inclusion in the COS were sought by the 
meeting chair, who also ensured that participants had 
equal opportunity to comment prior to voting. Voting 
was undertaken anonymously using Poll Everywhere30 
software, which was linked to mobile and tablet devices. 
The definition of consensus used in the Delphi Survey 
(table 1) was applied to the consensus meeting. The final 
COS was presented at the end of the meetings.
Study registration, ethics and reporting guidance
The study was prospectively registered with the COMET 
Initiative.31 Ethical approval was obtained from the 
University of Liverpool institutional research ethics 
committee for the focus groups, online survey and 
consensus meetings to be undertaken with healthcare 
professionals and patients (ref. numbers: 2063 and 
2260). Informed consent was obtained from participants. 
The study is reported in line with the Core Outcome 
Set—Standards for Reporting guidance32 (online supple-
mental table 2).
Patient and public involvement
The study was supported by a patient advisory group, 
which provided input to this research study. The patient 
advisory group met on a regular basis for the duration 
of the study. Patients contributed to the design of the 
study and were involved at all stages of the survey and 
consensus meetings.
RESULTS
A summary of the COS development process is shown 
in figure 1. The final COS contains ten, nine and ten 
outcomes across seven, six and seven domains for 
amblyopia, strabismus and ocular motility, respectively 
(tables 2–4). Ocular alignment, vision- related quality of 
life, adverse events and cost were common to all three 
conditions.
Development of the databank of outcomes
The systematic review and focus groups of healthcare 
professionals, researchers, patients and carers identi-
fied 31, 61 and 78 individual outcomes for amblyopia, 
strabismus and ocular motility, respectively. These were 
combined with a list of outcomes suggested by profes-
sional experts (SA- J and FJR) resulting in a total of 40, 70 
and 106 outcomes for amblyopia, strabismus and ocular 
motility, respectively. The outcomes were classified into 
12 domains (symptoms, visual function, refraction, oculo-
motor function, quality of life, treatment dependency, 
signs, investigations, long- term outcome, compliance, 
adverse events and cost), and outcomes that were not 
considered to be patient relevant were separated out or 
combined. As an example, ‘refractive status’, ‘spherical 
and cylindrical refraction’ and ‘median spherical equiv-
alence’ were combined into a single outcome ‘refractive 
status’ for patients as they all have a similar meaning but 
are often referred to separately by healthcare profes-
sionals. Details of all outcomes including domain clas-
sification, combined outcomes and plain language 
descriptions of outcomes are provided in online supple-
mental table 1.
Table 1 Definition of consensus
Consensus 
classification Description Definition of consensus
Consensus in Consensus that the outcome should be included in 
the core set
≥70% of participants scoring the outcome as ‘7–9’ 
(critically important)
Consensus out Consensus that the outcome should not be included 
in the core set
≥70% of participants scoring the outcome as ‘1–3’ 
(not important)
No consensus Uncertainty about the importance of the outcomes Anything else
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Online Delphi
Thirty- three healthcare professionals/researchers scored 
all outcomes for both R1 and R2 of the amblyopia 
component of the online survey, while 29 completed 
for strabismus and ocular motility. Three patients/
carers completed both rounds for amblyopia, while nine 
completed both rounds for strabismus and five for ocular 
motility (figure 1). At the end of R1, five outcomes for 
amblyopia, 12 for strabismus and 23 for ocular motility 
reached consensus ‘in’ for both stakeholder groups. 
After a review of all additional outcomes suggested by 
participants in R1, three new outcomes were added to 
the strabismus survey in R2 (improvement in angle by a 
set amount (suggested by a healthcare professional) and 
immediate result post surgery and long- term discomfort 
from scar tissue (both suggested by a patient)).
On completion of R2, ten outcomes reached consensus 
‘in’ for amblyopia across both stakeholder groups, while 
17 and 32 outcomes reached the same criteria for stra-
bismus and ocular motility, respectively.
Consensus meeting
Six, nine and seven voting participants attended the 
consensus meeting for amblyopia, strabismus and ocular 
motility, respectively, with an even balance of healthcare 
professional/researchers and patients present (figure 1).
Amblyopia
For amblyopia, future functionality/long- term impact and 
adverse events reached the consensus ‘in’ criteria for 
both stakeholder groups in both rounds of the Delphi 
and remained in the COS. Despite reaching consensus 
‘in’ for both rounds of the Delphi for both stakeholder 
groups, intolerable diplopia and occlusion amblyopia 
(both adverse events) were not included in the final 
COS as it was felt that these could be captured under 
‘adverse events’ and therefore were not critical for sepa-
rate inclusion in the COS. Long- term outcome was also 
excluded following discussion as the group felt that there 
was currently no agreed set time for measuring long- term 
objective outcomes. Best corrected visual acuity (BCVA) and 
compliance marginally did not reach consensus ‘in’ during 
R2 of the Delphi but made the final COS after discus-
sion. Following a discussion on the other visual function 
outcomes, near visual acuity was also added because it was 
noted that it was a good marker of early improvement for 
the treatment of amblyopia and important for children 
as it is important to their education. Refractive status 
reached consensus for both groups in R2, but following 
discussion, this was replaced by spherical and cylindrical 
refraction (scored only by healthcare professionals in the 
Delphi) because it was successfully argued that this was a 
more precise measurement of refractive status. The list of 
outcomes within the quality of life domain was discussed 
simultaneously. While this was not listed specifically as an 
outcome in the Delphi, participants agreed to include 
visual- related quality of life in the core set as it was felt that 
a generic health- related quality of life outcome was not 
sensitive enough. Psychological impact of treatment was 
scored only by healthcare professionals in the Delphi 
but reached consensus ‘in’ during R2. Following discus-
sion led by a parent participant, the panel derived a new 
outcome to include treatment- related impact into the final 
COS in order to capture the effect of treatment, such 
as patching on children, which could be long- lasting. 
For both Delphi rounds, cost outcomes did not reach 
consensus ‘in’ by either stakeholder groups; however, the 
consensus panellists successfully advocated for its inclu-
sion as a core outcome as cost outcome data are vital infor-
mation for contemporary health systems.
Strabismus
For strabismus, symptoms and patient satisfaction reached 
the consensus ‘in’ criteria for both stakeholder groups 
in both rounds of the Delphi and remained in the COS. 
BCVA also reached consensus ‘in’ for both rounds and 
groups in the Delphi although the consensus panel 
argued that any change in vision and/or loss of vision as 
an adverse event would be very significant and reportable 
as per standard healthcare safety procedures.33 At the 
consensus meeting, participants noted that strabismus 
interventions aim to change the strabismus angle and 
visual acuity (VA) should not be affected by the interven-
tion unless an adverse event occurred. Thus, a change in 
VA would be captured within adverse events. On this basis, 
a decision was taken to exclude VA from the core set. All 
remaining visual function outcomes were discussed simul-
taneously, and while the postop diplopia test reached 
consensus ‘in’ during the Delphi exercise, the consensus 
panel voted in favour of including binocular vision as core, 
as it was more representative of a group of visual- function- 
related outcomes. Oculomotor function outcomes were 
discussed simultaneously, and it was highlighted that 
ocular movement was critical to be reported in all strabismus 
types as a change caused by the intervention would be 
significant. Quantifying both the ocular alignment and devi-
ation was also seen to be critical in the context of any stra-
bismus type, and these were included as core outcomes. 
Visual- related quality of life, adverse events and cost were also 
included in the COS for reasons discussed for amblyopia.
Ocular motility
The discussions for ocular motility closely followed those of 
strabismus with the addition of clinical signs being added 
as an extra core outcome. Similar to adverse events, this 
outcome was a catch all for all clinical signs, which were 
scored individually in the Delphi exercise. This strategy 
was seen favourably by the meeting participants as many 
subconditions of ocular motility have specific signs associ-
ated with them. One example for this is corneal exposure 
in the ocular motility condition of thyroid eye disease but 
which is not relevant in other ocular motility disorders.
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DISCUSSION
This study has developed a set of core outcomes for the 
treatment of three ophthalmic conditions using a robust 
consensus process involving healthcare professionals, 
researchers, patients and carers. Consensus was reached 
on what should be measured in each of the three COS. 
They consisted of nine to ten outcomes distributed across 
six to seven domains to cover all important aspects related 
to treatment (objective clinical signs, adverse events, 
subjective or patient- reported outcomes and health 
economics). While these three COSs were developed 
independently, there are some parallels, and as a conse-
quence, four outcomes (ocular alignment, vision- related 
quality of life, adverse events and cost) were common to all 
three conditions. The amblyopia COS captures the condi-
tion’s unique features by reporting additionally on ‘best 
corrected visual acuity’, ‘near visual acuity’, ‘compliance’, 
‘spherical and cylindrical refraction’, ‘treatment- related 
impact’ and ‘future functionality/long- term impact’, 
keeping in mind that children are the predominantly 
affected population. The COS for strabismus and ocular 
motility disorders, on the other hand, include ‘binocular 
vision’, ‘ocular movement’, ‘measuring the deviation’, 
‘symptoms’ and ‘patient satisfaction’. The ocular motility 
disorder COS was unique in additionally reporting ‘clin-
ical signs’ related to the relevant conditions.
We recommend that, as a minimum, these core 
outcomes are used in future trials of interventions to 
treat amblyopia, strabismus and ocular motility disorders. 
We also advocate that these outcomes are recorded in 
routine clinical practice to ensure that the outcome data 
collected re meaningful and important.
A strength of this study is that it was prospectively 
registered with the COMET Initiative and it was 
developed using the COS- STAD recommendations.26 
Engagement with patient participants was particularly 
challenging, and we sought to improve patient input by 
offering paper copies of the Delphi Survey with prepaid 
return envelopes in orthoptic clinics, although this was 
later abandoned after a number of sessions when there 
was no uptake. As a consequence of a relatively low 
number of patients responding to the Delphi and attri-
tion between the two rounds, there was concern that 
consensus was not being achieved at the end of the final 
round given that the number of outcomes reaching 
consensus for both stakeholder groups had increased 
dramatically from R1. While measures were taken to 
ensure survey participation and retention were maxi-
mised (including sending reminders and extending 
deadlines for completion), it was felt that after several 
months of keeping the survey open, our efforts became 
futile. In order to compensate for this, we ensured that 
the consensus meetings where the final COS were rati-
fied contained a good balance of healthcare profes-
sionals and patients. The main limitation of this study 
was that the consensus process was based using only 
participants in the UK. However, as a starting point, 
Table 2 Final COS for amblyopia
Domain Outcome
Visual function 1. Best corrected visual acuity
2. Near visual acuity
Refractive status 3. Spherical and cylindrical refraction
Oculomotor function 4. Ocular alignment (is there an ocular deviation?)
Quality of life 5. Vision- related quality of life (for example, activities of daily living)
6. Treatment- related impact (for example, negative effects of patching on children during treatment)
7. Future functionality / long- term impact
Compliance 8. Compliance
Adverse events 9. Any adverse events (for example, intolerable diplopia, occlusion amblyopia)
Cost 10. Cost (for example, cost to services, families, and individuals)
Table 3 Final core outcome set for strabismus
Domain Outcome
Symptoms 1. Symptoms (eg, diplopia and appearance of 
the strabismus)




3. Ocular alignment (are the eyes straight?)
4. Measurement of deviation (what is the 
amount of deviation?)
5. Ocular movement (specifically incomitance, 
latent nystagmus, DVD and A&V pattern)
Quality of life 6.Vision- related quality of life: psychosocial 
aspects (such as self- esteem, confidence, 
behaviour and social interaction) and 
functional aspects (such as activities of daily 
living)
7.Patient satisfaction
Adverse events 8.Any adverse events (eg, intolerable diplopia, 
recurrence of the deviation and overcorrection 
or undercorrection of the deviation)
Cost 9.Cost (eg, cost to services, families, and 
individuals)
DVD - dissociated vertical deviation, A&V - A and V pattern
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we have reason to believe that this COS could also be 
useful in other countries and settings.
Further consensus work is needed to refine and estab-
lish the best measurement instruments and time points 
for when to measure these core outcomes. To assist this 
process, the systematic review for generating the databank 
of outcomes also recorded the measurement instruments 
and timings associated with each outcome.27 Moreover, 
for some outcomes, the metric (eg, change from baseline 
or interocular difference (IOD) of BCVA) and method 
of aggregation (eg, mean or median)22 would need to be 
determined. Defining success criteria (eg, 8 or 10 diop-
tres from orthophoria for alignment, for distance and/
or near) is another aspect of outcome refining and defi-
nition to be done by further work. The generalisability of 
the COS also needs to be reviewed in healthcare settings 
outside the UK. While the review of outcomes identified 
studies from around the world (with prominence from 
the USA, the UK, China and various European coun-
tries), the formal consensus process was undertaken 
using only participants from the UK, and those attending 
the consensus meeting were mostly localised to the North 
West of England.
There are few reported COSs in the literature that 
relate to the three conditions in this study. Chiu et al 
recommended four outcomes for reporting results of 
surgery for intermittent exotropia.34 Their study aimed 
to explore the extent of standardisation of outcomes 
reported in surgical studies for the condition. However, 
the study was limited by the extent of literature review for 
this specific condition (10- year literature search period) 
and lack of external consensus. A short narrative review 
of outcome measurements for size of deviation showed 
considerable variability across the tests available and the 
recommendations for their use. They suggested four core 
outcomes for all future studies: alignment, near stereo-
acuity, control score and quality of life score. If assigning 
near stereoacuity and control score to ‘binocular vision’, 
their outcomes map to those reported in our COS for 
strabismus.
Moreover, two recently published studies attempted to 
define criteria for success in treatment, one for ambly-
opia and the other for strabismus surgery, which could 
be considered complementary to the COS and not alter-
natives because they essentially give more definitions of 
primary outcomes rather than suggesting a set of specific 
outcomes to be measured in research.
A report was published by Shoshany et al35 stated that the 
IRIS measures for amblyopia developed by the American 
Academy of Ophthalmology (IRIS7,36 modified in 2019 to 
IRIS5035) provide uniform criteria for defining amblyopia 
treatment success. Treatment was defined as ‘successful’ if 
corrected IOD was less than 0.23 logMAR 12–18 months 
after first diagnosis. IRIS50 considers improvement in VA, 
which may be relevant to patients who had dense ambly-
opia at baseline but nevertheless improved. Thus, IRIS50 
may be a more practical reporting measure than IRIS7. In 
general, Shoshany et al propose that these measures will 
allow more efficient reporting of quality metrics and rapid 
and objective assessment of new amblyopia treatments.35
In addition, a study aiming to define successful outcomes 
for strabismus surgery was published by Serafino et al.37 
Although this study did not state an intention to develop 
a COS, there are a lot of similarities and overlap in the 
objectives and methodology used. A Delphi process was 
used to identify areas of consensus and disagreement 
among experts for the definition of success post strabismus 
surgery. The panel of experts in their study represented 
wide international geographical areas and included 
experts who were chosen based on their peer- reviewed 
publications, participation at international meetings and 
surgical experience. The study concluded the following: 
they achieved consensus on which strabismus types need 
their separate set of outcome criteria. They also identi-
fied the importance of ‘stereopsis’ and ‘the range of 
single vision’ for inclusion of success definition in some 
Table 4 Final core outcome set for ocular motility disorders
Domain Outcome
Symptoms 1. Symptoms (eg, diplopia and appearance of the eye deviation)
Visual function 2. Binocular vision (eg, stereoacuity, field of binocular single vision and postop diplopia test)
Oculomotor function 3. Ocular alignment (are the eyes straight?)
4. Measurement of deviation (what is the amount of deviation?)
5. Ocular movement (specifically incomitance, latent nystagmus, DVD and A&V pattern)
Quality of life 6. Vision- related quality of life: psychosocial aspects (such as self- esteem, confidence, behaviour and 
social interaction) and functional aspects (such as activities of daily living)
7. Patient satisfaction
Adverse events 8. Any adverse events (eg, intolerable diplopia, recurrence of the deviation and adverse effects from 
patches or prisms)
Cost 9. Cost (eg, cost to services, families and individuals)
Clinical signs 10.Clinical signs (eg, corneal exposure, proptosis/exophthalmos and enophthalmos)
DVD - dissociated vertical deviation, A&V - A and V pattern
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strabismus types, which interestingly could be mapped to 
‘binocular vision’ in our strabismus COS. The study also 
found that there was no consensus on the length of time 
after surgery for determination of success, magnitude of 
deviation consistent with success and whether manifest or 
latent deviation should be considered to define success, 
which the review of our study27 has also found and which 
we are advocating to define, by future work. Differences 
from our study are that their survey did not involve 
scoring of outcomes, there was no systematic search of 
literature of reported outcomes prior to survey construc-
tion and patients or service users were not consulted in 
the process.
A search in the COMET Initiative database in April 
2020 did not reveal registration of any further additions 
of similar studies in the database. It is advantageous to 
register COS studies in the database to facilitate collab-
orative work of similar scope and to avoid duplication of 
efforts and waste of research.
CONCLUSION
The three COSs developed from this study can be applied 
to future trials and routine data collection for all inter-
vention types to treat the three ophthalmic conditions 
considered. Their use will allow the comparison of 
outcome data to be made across studies and to better 
inform treatment decisions. Future work will include 
seeking consensus on how these outcomes should be 
measured and to evaluate the acceptability of the current 
COS to patients and professionals in other countries, 
particularly where healthcare systems differ from the UK.
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